Skip to main content
Fig. 5 | Experimental Hematology & Oncology

Fig. 5

From: Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL

Fig. 5

Transient cytokine release primarily occurs during the first days after start of blinatumomab therapy. Mean ± SD serum concentrations of IL-2 (a), IL-6 (b), IL-10 (c), TNF-α (d), and IFN-γ (e) from all evaluable patients during the first treatment week of each of the first three cycles. Corresponding patient numbers are shown in Additional file 5

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us